TauroPharm GmbH of Waldbüttelbrunn at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers

TauroPharm GmbH

August-Bebel-Str. 51, 97297 Waldbüttelbrunn
Germany
Telephone +49 931 304299-0
Fax +49 931 304299-29
info@tauropharm.de

Hall map

MEDICA 2018 hall map (Hall 7): stand B36

Fairground map

MEDICA 2018 fairground map: Hall 7

Our range of products

Product categories

  • 05  Commodities and Consumer Goods
  • 05.10  Catheters / urinary catheters and accessories

Catheters / urinary catheters and accessories

Our products

Product category: Catheters / urinary catheters and accessories

TauroLock™

INDICATION AND EFFECT:
TauroLock™ is approved for instillation in all central venous access systems. TauroLock™ remaining in the catheter prevents the formation of a bacterial biofilm. The catheter stays infection-free.

COMPOSITION:
The lock solution contains (cyclo)-taurolidine and citrate (4%). (Cyclo)-taurolidine has a broad antimicrobial activity (incl. MRSA and VRE) against gram-positive and gram-negative bacteria and fungi (e.g. Candida).

PACKAGE SIZES:
TauroLock™ is available in ampoules (single use): 3 mL and 5 mL (10 ampoules per box), and in vials (multiple use): 10 mL (100 vials per box).

EXPERT RECOMMENDATIONS:
TauroLock™ complies with the recommendations for the use of antimicrobial lock solutions (see Literature). We recommend TauroLock™-Hep500 for dialysis access systems.

APPLICATION:
Between dialysis sessions or in application-free periods (oncology, parenteral nutrition), TauroLock™ is instilled into the saline-rinsed access system. The filling volume of the catheter/port system should be noted in this context.

More Less

About us

Company details

TauroPharm GmbH is a life science company specialized in antimicrobial medical devices. One of the company’s core interests is to offer a safe and effective technology for locking central venous access devices (catheters and ports).

TauroLock TM , a non-antibiotic lock solution, which is capable of dramatically reducing catheter related blood stream infections (CRBSI) is free of side-effects. The active compound is taurolidine which is not an antibiotic, but a derivative of an amino acid. TauroLock TM is highly effective in eradicating bacteria and fungi and has been successfully tested on more than five hundred organisms, including multi resistant forms such as MRSA and VRE. It is to be used in dialysis, oncology, intensive care and parenteral nutrition.

To improve catheter patency TauroLock TM products contain 4% citrate and in addition heparin or urokinase.

More Less